Quick Takeaways
- Frazier Life Sciences Public Fund, L.P. filed SCHEDULE 13G/A for Maze Therapeutics, Inc. Common Stock, par value $0.001 per share (MAZE).
- Disclosed ownership: 9.4%.
- Date of event: 31 Mar 2025.
Quoteable Key Fact
"Frazier Life Sciences Public Fund, L.P. disclosed 9.4% ownership in Maze Therapeutics, Inc. Common Stock, par value $0.001 per share (MAZE) on 31 Mar 2025."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Frazier Life Sciences Public Fund, L.P. | 7% | 3,044,573 | 0 | 3,044,573 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P. | |
| FHMLSP, L.P. | 7% | 3,044,573 | 0 | 3,044,573 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P. | |
| FHMLSP, L.L.C. | 7% | 3,044,573 | 0 | 3,044,573 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLSP, L.L.C. | |
| Frazier Life Sciences Public Overage Fund, L.P. | 2.1% | 898,383 | 0 | 898,383 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P., GP of Frazier Life Sciences Public Overage Fund, L.P. | |
| FHMLSP Overage, L.P. | 2.1% | 898,383 | 0 | 898,383 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P. | |
| FHMLSP Overage, L.L.C. | 2.1% | 898,383 | 0 | 898,383 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C. | |
| Frazier Life Sciences X, L.P. | 0.2% | 66,677 | 0 | 66,677 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P. | |
| FHMLS X, L.P. | 0.2% | 66,677 | 0 | 66,677 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P. | |
| FHMLS X, L.L.C. | 0.2% | 66,677 | 0 | 66,677 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLS X, L.L.C. | |
| Frazier Life Sciences XI, L.P. | 0.3% | 119,367 | 0 | 119,367 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P. | |
| FHMLS XI, L.P. | 0.3% | 119,367 | 0 | 119,367 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P. | |
| FHMLS XI, L.L.C. | 0.3% | 119,367 | 0 | 119,367 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLS XI, L.L.C. | |
| James N. Topper | 9.4% | 4,129,000 | 0 | 4,129,000 | /s/ Steve R. Bailey | By Steve R. Bailey, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017 | |
| Patrick J. Heron | 9.4% | 4,129,000 | 0 | 4,129,000 | /s/ Steve R. Bailey | By Steve R. Bailey, Attorney-in-Fact for Patrick J. Heron, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017 | |
| Albert Cha | 9% | 3,942,956 | 0 | 3,942,956 | /s/ Steve R. Bailey | By Steve R. Bailey, Attorney-in-Fact for Albert Cha, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021 | |
| James Brush | 9% | 3,942,956 | 0 | 3,942,956 | /s/ Steve R. Bailey | By Steve R. Bailey, Attorney-in-Fact for James Brush, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021 | |
| Daniel Estes | 0.3% | 119,367 | 0 | 119,367 | /s/ Steve R. Bailey | By Steve R. Bailey, Attorney-in-Fact for Daniel Estes, pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022 |